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Chronic Venous 
Chronic Venous insufficiency (CVI) is a common disease with significant morbidity 
that results from venous hypertension of the extremities. Increased perfusion pressure 
probably traps excessive numbers of white blood cells in the capillaries. 
Activated leukocytes subsequently damage capillary 
endothelium, increase capillary permeability, and cause 
ischemia of overlying skin as a result of leakage of 
fibrinogen and formation of a fibrin cuff. Diagnosis of 
CVI is not difficult because its clinical manifestations 
are usually evident. 
In addition to poor cosmetic appearance, CVI can lead 
to chronic life-threatening infections of the lower 
extremities. Pain, especially after ambulating, is a 
hallmark of the disease. CVI causes characteristic changes, 
called Lipodermatosclerosis, to the skin of the lower 
extremities, which lead to eventual ulceration. 
Epidemiology 
Peak incidence occurs in women aged 40-49 years and 
in men aged 79-79 years. l A high percentage of Maltese 
population has symptoms due to CVI, which can lead 
to skin changes and venous stasis ulcers. 
Clinical manifestations include the following: 
• Varicose veins: In addition to poor cosmetic 
appearance, varicose veins serve as indicators of venous 
hypertension. Most women with superfiCial varicose 
veins complain of their unSightly appearance; 
• Leg discomfort: Venous hypertension in muscles of 
the lower leg from exercise and prolonged standing is 
the characteristic ache of CVI. The discomfort is 
described as pain, pressure, burning, itching, dull ache, 
or heaviness in affected calves or legs; 
• Ulcers: Typically, these lesions occur around the medial 
malleolus, where venous pressure is maximal due to the 
presence of large perforating veins; 
• Edema of the lower extremities caused by venous 
insufficiency is one of the most frequent symptoms of 
this pathology; 
• Lipodermatosclerosis: These characteristic skin changes 
in the lower extremities include capillary proliferation, 
fat necrosis, and fibrosis of skin subcutaneous tissues. 
Skin becomes reddish or brown because of the deposition 
of hemosiderin from red blood cells. 
Risk factors associated with chronic venous insufficiency 
• Age: Incidence of CVI rises substantially with age; 
• Family history: History of deep vein thrombosis 
(DVT), which renders venous valves incompetent, 
causing backflow and increased venous pressure, is a risk 
factor; 
• Pregnancy: 8-40% of the pregnant women encounter 
it for the first time during pregnancy;2 
Lifestyle: A sedentary lifestyle minimizes the pump 
action of calf muscles on venous return, causing higher 
venous pressure. CVI occurs more frequently in women 
who are obese. Vocations that involve standing for long 
periods predispose individuals to increased venous 
pressure in dependant lower extremities. A higher 
incidence of CVI is observed in men who smoke. 
Surgery - Surgical trea tment consists of removing the 
varicosities and the incompetent perforating veins, but 
is limited to persons with patent del'p veins. Bpfof'l' 
1985, surgery on incompetent perforator veins in patients 
with Sl'vere, chronic, venous insufficil'ncy and venous 
ulcerations was generally pl'rformed utilizing long skin 
incisions through diseased skin and subcutaneous tissul's. 
Known as "the Linton operation", wound infections and 
poor healing complicated this procedure. Today a new 
surgical technique for identifying and ligating 
incompetent perfora tor veins is being utilized using an 
endoscopic approach in the limbs' subfascial space. :l 
Injection Sclerotherapy - Although the main treatment 
for varicose veins with proximal venous reflux is surgery, 
it is not possible to do the same for the small veins that 
run into the skin. The aim of treatml'nt is to obliterate 
them by not letting blood run through them. Sclerosant 
agents such as sodium tetradecyl sulphate (FibroVein ") 
is injected into the collapsed superficial vein where the 
chemical exerts its effect on the endothelium, causing 
swelling of its lining cells, with formation of red 
thrombus inside the lumen . The thrombus is gradually 
absorbed, but scar tissue forms, which occludes the 
lumen and the vein sl'gment becomes oblitl'rated (usually 
in 3-4 weeks) .1 ', 
Lasers - Laser and Pulsed Light treatments are being 
used as an alternative to or to complelllent sclerotherapy 
for slllall veins. They all work on the same basic principle: 
a light beam is pulsed onto the veins in order to sea l 
them off. Successful light -based treatllll'nt requires 
adequate hl'ating of the veins. Se v !'J'a I treatments an' 
usually needed for optilllal results. 
Pharmaceuticals - Phlebotropic agl'nts like dioslllin act 
by reducing the recapturl' of noradrenalin by tl](' nerve 
Illuscles cells. There is therefore more of the Illl'diator, 
Noradrenalin, which can act on tl](' receptors. The 
concentration of myocy tes is then'fo re extl'nded. 
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